Skip to main content

Peer Review reports

From: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis

Original Submission
13 Aug 2019 Submitted Original manuscript
25 Aug 2019 Reviewed Reviewer Report - Wentong Fang
8 Sep 2019 Reviewed Reviewer Report - Ha Le
1 Oct 2019 Author responded Author comments - Kerry Mansell
Resubmission - Version 2
1 Oct 2019 Submitted Manuscript version 2
2 Oct 2019 Reviewed Reviewer Report - Wentong Fang
11 Oct 2019 Author responded Author comments - Kerry Mansell
Resubmission - Version 3
11 Oct 2019 Submitted Manuscript version 3
21 Oct 2019 Author responded Author comments - Kerry Mansell
Resubmission - Version 4
21 Oct 2019 Submitted Manuscript version 4
23 Oct 2019 Author responded Author comments - Kerry Mansell
Resubmission - Version 5
23 Oct 2019 Submitted Manuscript version 5
Publishing
25 Oct 2019 Editorially accepted
12 Nov 2019 Article published 10.1186/s12913-019-4680-2

You can find further information about peer review here.

Back to article page